You are here: Home / Research & Faculty / Core Facilities / Human Antibody Core Facility

The mission of the Human Antibody Core Facility at OMRF is to:

  • Successfully collaborate with OMRF, OUHSC and external investigators to define temporal human immune responses after vaccination and to generate human monoclonal antibodies to supplement their research.
  • Develop novel methods to produce human monoclonal antibodies after acute infection and other immune events.
  • Investigate new technologies for the characterization of human monoclonal antibodies produced by the core.

The Human Antibody Core Facility is one of the few laboratories in the world that produces fully-human, full-length, antigen-specific antibodies for use in studying human immune responses.  The Core has achieved breakthroughs in antibody technology and has produced hundreds of high affinity protective antibodies to influenza, anthrax lethal toxin, and various S. pneumonia polysaccharides.  The Core aims to support investigators by helping quantify the antibody secreting cell responses after vaccination and by generating human monoclonal antibodies to be characterized.  Pathogen-specific human monoclonal antibodies are also available for licensing agreements and other forms of commercial development.  The Core is expanding these services to aid additional clinical and basic science investigators inside and outside Oklahoma.

Key Faculty

Core Director:  Kenneth Smith, Ph.D.

Faculty Supervisor: Judith A. James, Ph.D.

Senior Faculty Consultants: J. Donald Capra, M.D., and Linda Thompson, Ph.D.

Process Developed by: Patrick C. Wilson, Ph.D.

 

The Human Antibody Core Facility provides the following services at this time:

  • 20 Antibodies from ASCs After Vaccination (HAC does sort)
  • 20 Antibodies from ASCs After Vaccination (customer does sort)
  • Cloning of Antibodies (mouse or human) Into Expression Vector
  • Expression of Antibodies (human or humanized):
     

  • 4-plate transfection (50-500 micrograms of product)
  • 20-plate transfection (250-2500 micrograms of product)
  • 40-plate transfection (500-5000 micrograms of product)
  • 80-plate transfection (1-10 milligrams of product)

    •  

  • Elisa (1-4 plates, customer supplies antigen)
  • Hybridoma Sequencing
  • Site-specific Mutagenesis or Reversion of Antibody or Germline
  • Non-antibody Protein Express (in HEK293 or BL21)

 
Pricing is done on a project-specific basis, and an Agreement for Services will be provided once the price for the requested services has been determined.

The Human Antibody Core Facility is located on the first floor of the Oklahoma Medical Research Foundation, Acree-Woodworth Building:

825 NE 13th Street
Oklahoma City,OK 73104
Mail Stop:  53
Telephone:  (405) 271-3275

Additional Staff Contact information:

Smithk Contact UsKenneth Smith, Ph.D.
Research Assistant Member
Core Director
Ken-Smith@omrf.org

mutherj Contact UsJennifer Muther
Senior Research Technician
Jennifer-Muther@omrf.org

dukea Contact UsAngie Duke
Senior Research Assistant
Angie-Duke@omrf.org

mckeee Contact UsEmily McKee
Senior Research Technician
Emily-McKee@omrf.org

Peer-Reviewed Microarray Publications from the OMRF Human Antibody Core Facility

Smith K, Wrammert J, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air G, Capra JD, Ahmed R, Wilson PC.  Rapid Cloning of High-affinity Human Monoclonal Antibodies Against Influenza Virus.  Nature.  2008 May 29; 453(7195): 667-71.

Smith K, Garman L, Wrammert, J, Zheng NY, Captra JD, Ahmed R, Wilson PC.  Rapid Generation of Fully Human Monoclonal Antibodies Specific to a Vaccinating Agent.  Nat Protoc.  2009; 4(3): 372-84.

Smith K, Crowe SR, Garman L, Guthridge CJ, Muther JJ, McKee E, Zheng NY, Farris AD, Guthridge JM, Wilson, PC, James JA.  Human Monoclonal Antibodies Generated Following Vaccination with AVA Provide Neutralization by Blocking Furin Cleavage But Not by Preventing Oligomerization.  Vaccine.  2012 March 14 [Epub ahead of print].